Breast cancer patients are stratified into different molecular subtypes with respect to the expression of nuclear hormone receptors (i.e., estrogen receptor (ER) and progesterone receptor (PR), and epidermal growth factor receptor (Her2). This evidence concerns the gene EGFR and breast cancer.